# A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

> **NCT02955212** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 338 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02955212
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-03
- **Primary completion:** 2019-08-14
- **Final completion:** 2020-09-03
- **Target enrollment:** 338 (ACTUAL)
- **Last updated:** 2021-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02955212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02955212, "A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02955212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*